Canadian application, no grantCanada
Naaladase inhibitors for treating retinal disorders and glaucoma
CA 2410889 A1 · Owner: Mgi Gp, Inc. · Inventors: Wozniak, Krystyna; Slusher, Barbara S.
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 30, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 30, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 30, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledMay 30, 2001
GrantedNo grant recorded
Term endedMay 30, 2021
Patent numberCA 2410889 A1
Classification (IPC)A61K31/19 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.